News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Subscribe To Our Newsletter & Stay Updated
